Bristol Myers: FDA approves Breyanzi for leukemia
In TRANSCEND CLL 004, the first multicenter pivotal trial to evaluate CAR-T cell therapy in patients with relapsed or refractory CLL or CLL, 20% of patients treated with Breyanzi achieved a complete response (CR) with a median duration of CR not reached, as well as an established safety profile.
' 'CAR-T cell therapies represent a transformative treatment option for patients with certain types of blood cancers,' said Bryan Campbell, senior vice president, commercial lead, cell therapy, Bristol Myers Squibb.
' For years, attempts to bring other CAR-T cell therapies to patients with relapsed or refractory CLL or SLL have met with difficulty and little success. With the approval of Breyanzi as the first CAR T for relapsed or refractory CLL or CLL, we are now able to offer these patients a personalized option, while expanding access to the broadest range of B-cell malignancies, to address this critical unmet need.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction